Early Phase 1
๐ Investigational Drug / Biologic
NCT06684522
Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
๐ Northwestern University Department of Dermatology โ Chicago, Illinois
View Study & Screener โ